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A B S T R A C T
Diabetes mellitus potentiates the risk of breast cancer. We have previously described the pro-tumorigenic eﬀects
of advanced glycation endproducts (AGEs) on estrogen receptor (ER)-negative MDA-MB-231 breast cancer cell
line mediated through the receptor for AGEs (RAGE). However, a predominant association between women with
ER-positive breast cancer and type 2 diabetes mellitus has been reported. Therefore, we have investigated the
biological impact of AGEs on ER-positive human breast cancer cell line MCF-7 using in vitro cell-based assays
including cell count, migration, and invasion assays. Western blot, FACS analyses and quantitative real time-PCR
were also performed. We found that AGEs at 50–100 μg/mL increased MCF-7 cell proliferation and cell mi-
gration associated with an enhancement of pro-matrix metalloproteinase (MMP)-9 activity, without aﬀecting
their poor invasiveness. However, 200 μg/mL AGEs inhibited MCF-7 cell proliferation through induction of
apoptosis indicated by caspase-3 cleavage detected using Western blotting. A phospho-protein array analysis
revealed that AGEs mainly induce the phosphorylation of extracellular-signal regulated kinase (ERK)1/2 and
cAMP response element binding protein-1 (CREB1), both signaling molecules considered as key regulators of
AGEs pro-tumorigenic eﬀects. We also showed that AGEs up-regulate RAGE and ER expression at the protein and
transcript levels in MCF-7 cells, in a RAGE-dependent manner after blockade of AGEs/RAGE interaction using
neutralizing anti-RAGE antibody. Throughout the study, BSA had no eﬀect on cellular processes. These ﬁndings
pave the way for future studies investigating whether the exposure of AGEs-treated ER-positive breast cancer
cells to estrogen could lead to a potentiation of breast cancer development and progression.
1. Introduction
Diabetes mellitus is a major public health concern with an in-
creasing high prevalence and incidence that represents the seventh
leading cause of death in the US, European nations and developed
countries [1–3]. Type 2 diabetes mellitus is the most common form and
a long-term chronic metabolic disorder characterized by hypergly-
cemia, mainly due to untreated insulin resistance [4]. During hy-
perglycemia, increased glycation of macromolecules (proteins, lipids or
nucleic acids) occurs and leads to the formation of so called advanced
glycation endproducts (AGEs) [5]. These AGEs are complex, ﬂuorescent
and crosslinked molecules of pathological signiﬁcance [6]. Although
this hyperglycemia-induced glycation is a non-speciﬁc reaction,
proteins undergo this modiﬁcation more frequently than other macro-
molecules, with substantial functional and structural consequences
[7–11]. Diﬀerent clinical studies have reported the role of AGEs in the
pathogenesis of various types of cancers in patients with diabetes
mellitus, including colorectal [12], kidney [13], and liver cancer [14].
Lately, a growing body of evidence has suggested the direct con-
sequences of diabetes-related hyperglycemia and hyperinsulinemia as
AGEs can increase the development and progression of breast cancer
[15–17].
Breast cancer is the second common cause of death with the highest
incidence in women worldwide. This heterogeneous malignancy is
characterized by a high diversity of morphological, molecular and
biochemical features inﬂuencing disease progression, prognosis and
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response to therapy [18]. Breast cancer subtypes are classiﬁed based on
whether they are hormone- or non-hormone-dependent and referred for
instance as estrogen receptor (ER)-positive or ER-negative, respectively.
Of note, about 70% of breast cancer cases are ERα-positive [19].
Moreover, a growing body of evidence show that aerobic tumor cells
are largely dependent on glycolysis, rather than oxidative phosphor-
ylation, for their energy supply, a phenomenon known as the Warburg
eﬀect [20]. This altered energy metabolism generates cytotoxic sugar-
derived reactive carbonyl compounds such as methylglyoxal, which
promotes AGE formation in cancer cells [21]. Marked increases in the
methylglyoxal and AGEs generated have been detected and correlated
with breast cancer progression [22].
The cellular eﬀects of AGEs are mainly mediated through the re-
ceptor for AGEs (RAGE) [23]. Highly expressed during embryonic de-
velopment, RAGE expression level is low in the majority of healthy
adult tissues while its expression is induced in pathological conditions
(i.e. hyperglycemia, oxidative stress, hypoxia, inﬂammation) [24–26].
AGEs-RAGE interaction leads to the activation of signaling pathways
(e.g., extracellular-signal regulated kinase [ERK]1/2, protein kinase C,
cAMP response element binding protein-1 [CREB1], phosphoinositol-3
kinase [PI-3K], nuclear factor [NF]-κB phosphorylation) resulting in the
production of inﬂammatory mediators that stimulate various cellular
functions capable of promoting cancer [23,27]. We previously showed
that methylglyoxal-derived bovine serum albumin AGEs (MG-BSA-A-
GEs) increased the proliferation, migration and invasion of ER-negative
MDA-MB-231 breast cancer cell line, in a RAGE-dependent manner
[17].
Meta-analysis and cohort studies have reported that breast cancer
rates are higher among women diagnosed with type 2 diabetes mellitus
(the most common form of this condition) than among their non-dia-
betic counterparts, particularly at post-menopausal stages [28–29].
Based on epidemiological studies, women with diabetes mellitus seem
to be at greater risk of developing breast cancer during the pre-diabetes
phase and because of low circulatory estrogen level [30–31]. It has been
reported that the association between type 2 diabetes mellitus and
breast cancer was signiﬁcant among women with ER-positive tumors
[32]. To improve the therapy and management of diabetic patients
diagnosed with breast cancer, a better understanding of the interaction
between AGEs in diabetes mellitus and ER-positive breast cancer cells is
of great interest. Thus, in this present study, we investigated the bio-
logical impact of AGEs on the ER-positive MCF-7 breast cancer cells, on
their cellular function, signal transduction, and RAGE and ER expres-
sion.
2. Materials and methods
2.1. Reagents
All reagents were obtained from Sigma-Aldrich (Dorset, UK), unless
indicated otherwise.
2.2. Preparation of MG-BSA-AGEs
Methylglyoxal-derived bovine serum albumin advanced glycation
endproducts (MG-BSA-AGEs) and non-modiﬁed BSA were prepared as
described previously [17].
2.3. Culture of MCF-7 breast cancer cells
The MCF-7 breast cancer cell line was obtained from American Type
Culture Collection (Manassas, VA, USA) and cultured in complete
medium comprising Dulbecco's Modiﬁed Eagle's Medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS),
2 mM glutamine and antibiotics (100 μg/mL streptomycin and 100 IU/
mL penicillin) at 37 °C in a saturated humid air/5% CO2 incubator.
2.4. Cell proliferation assay
MCF-7 cells (2.5 × 104 mL) were seeded in 24-well plates (Nunc™,
Fisher Scientiﬁc, Loughborough, UK) in complete medium. The ex-
perimental conditions were applied for 72 h of incubation as previously
described [17]. Each condition was performed in duplicate, and each
experiment was repeated independently three times. The untreated and
MG-BSA-AGEs-treated cells were then counted using a Beckman-
Coulter counter (Buckinghamshire, UK). The cell viability was eval-
uated using an automated cell counter TC10 (Bio-Rad, Munich, Ger-
many), based on the trypan blue exclusion method.
2.5. Directional cell migration and invasion assays
The Boyden chamber system composed of Transwell® inserts
(Nunc™) in a 24-well plate was used to assess MCF-7 cell migration and
invasion across a porous membrane (8 μm pore size) coated with ge-
latin and a reconstituted basement membrane (Matrigel™; Becton
Dickinson, Oxford, UK), respectively. Either gelatin (0.1% v/w) or
growth-factor reduced Matrigel™ (1:6 dilution) was diluted in serum-
free medium and then poured onto the porous membrane of the insert
plate as described previously [17]. Each condition was performed in
duplicate, and each experiment was repeated independently at least
three times. The migrated or invaded cells were ﬁxed with 4% paraf-
ormaldehyde, stained with a 0.1% solution of Giemsa, and counted
using a Zeiss optical microscope.
2.6. Gelatin zymography
Matrix metalloproteinase (MMP) activities in the cell-culture media
which had been used for cell invasion assay were evaluated. The
medium was collected and centrifuged (600 ×g for 15 min at 4 °C).
Protein concentration was determined using the Bradford protein assay
(Bio-Rad), and the samples (100 μg of protein) were mixed with an
equal volume of non-reducing sample buﬀer. From protein concentra-
tion determination to the destaining of the gels, the zymography
method used has been described previously [17]. In order to identify
the corresponding MMP, in addition to their molecular size, re-
combinant human (rh) MMP-2 (ab81550) and rhMMP9 (ab82955)
purchased from Abcam (Cambridge, UK) were analysed along with the
protein samples. MMP gelatinase activity was detected as a white band
on a dark background and quantiﬁed by densitometry using Image J
software (http://rsbweb.nih.gov/ij/index.html).
2.7. Preparation of cell lysates and Western blot analysis
MCF-7 cells (6 × 105/2 mL) were seeded in 6-well plates (Nunc™)
in complete medium. After 48 h of incubation, the medium was re-
newed with serum-poor medium (SPM; medium supplemented with
2.5% FBS) for an additional 24-hour incubation, and MG-BSA-AGEs or
non-modiﬁed BSA were added and incubated for diﬀerent time periods
(from 10 min to 72 h). Each condition was performed in duplicate, and
each experiment was repeated independently three times. Cell lysate
preparation, protein separation by 12% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transfer of separated proteins to
polyvinylidene diﬂuoride membranes were performed as previously
described [17]. The membranes were then incubated overnight at 4 °C
on a rotating shaker in the presence of primary antibody, which had
been diluted in blocking buﬀer (1% BSA in Tris-buﬀered saline
[TBS]–Tween]. Mouse monoclonal antibody against phospho-extra-
cellular signal-regulated kinase (p-ERK1/2 [E-4], Tyr204 of ERK1, sc-
7383; 1:1000 dilution), rabbit polyclonal antibodies to total ERK1/2 [C-
16] (t-ERK1/2, sc-93; 1:1000), and mouse monoclonal antibodies to
RAGE [E-1] (sc-74,473; 1:1000 dilution) were provided by Santa Cruz
Biotechnology (Heidelberg, Germany). Mouse monoclonal antibodies to
GAPDH [6C5] (ab8245; 1:2000 dilution), rabbit polyclonal antibodies
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to estrogen receptor-β (ab5786; 1:1000) and rabbit monoclonal anti-
bodies to estrogen receptor-α [E115] (ab32063; 1:1000) were pur-
chased from Abcam (Cambridge, UK). Rabbit monoclonal antibodies to
cleaved caspase-3 [5A1E] (#9664; 1000 dilution) and to caspase-3
[8G10] (#9665; 1000 dilution) were provided by Cell Signaling Tech-
nology (Danvers, MA, USA). The primary antibodies were detected with
infrared ﬂuorescent (red) IRDye® 680RD-conjugated goat anti-rabbit or
(green) IRDye® 800RD-conjugated goat anti-mouse secondary anti-
bodies (LI-COR Biosciences, Lincoln, NE, USA) diluted in TBS-Tween
containing 3% BSA (1:1000 dilution) for 1 h at room temperature with
continuous mixing. After ﬁve washes in TBS-Tween, the proteins were
scanned and analyzed using the Odyssey CLx Scanner equipped with
Image Studio software (LI-COR Biosciences).
2.8. Kinexus phospho-protein array analysis
MCF-7 cells (6 × 105/2 mL) were seeded in 6-well plates in com-
plete medium. After 24-hour incubation, the medium was changed to
SPM. After additional 24-hour incubation, 100 μg/mL MG-BSA-AGEs or
non-modiﬁed BSA were added, and the cells were then incubated for
10 min at 37 °C. To determine the protein expression proﬁles of sig-
naling components downstream of RAGE, a phospho-protein array
analysis (Kinetworks PhosphoSite Screen, KPSS-1.3) was performed in
triplicate by Kinexus Bioinformatics (Vancouver, Canada). Protein
samples (500 μg) from the MG-BSA-AGE-treated or non-modiﬁed BSA-
treated and untreated cells were extracted according to the manufac-
turer's instructions.
2.9. Flow cytometric analysis
MCF-7 cells (6 × 105/2 mL) were seeded in each well of a 6-well
plate in complete medium. After 24-hour incubation, the medium was
replaced with SPM for additional 24-hour incubation, and then 100 μg/
mL MG-BSA-AGEs were added and incubated for 72 h. Each condition
was performed in triplicate, and each experiment was repeated in-
dependently four times. The cells were washed with phosphate buﬀered
saline (PBS) and then scraped to maintain the intact structure of RAGE
(a transmembrane protein). The cells were washed with PBS and half of
the cells had their membranes permeabilized with 0.1% Triton X-100 in
PBS for 10 min following to ﬁxation with 3.7% formaldehyde for
10 min. After centrifugation (300 ×g for 10 min), 106 cells were re-
suspended in 20 μL of PBS, and then 20 μg/mL mouse anti-RAGE (E-1)
antibody or 2 μg of the mouse IgG1 isotype control (ab91353 from
Abcam) was added. The mixture was incubated on ice for 45 min, and
then the excess antibody was removed by washing the cells twice with
PBS, followed by centrifugation (300 ×g for 10 min, at 4 °C). After the
second centrifugation, the cells were re-suspended in 20 μL of PBS then
20 μg/mL of monoclonal anti-mouse antibody-FITC (Invitrogen,
Paisley, UK) was added, and the mixture incubated on ice for 30 min.
The RAGE expression level was measured using the FACS Diva analysis
software from the FACS Canto Flow Cytometer (Becton Dickinson).
2.10. RNA extraction and quantitative real-time (qRT)-PCR
MCF-7 cells (6 × 105/2 mL) were seeded in 6-well plates in com-
plete medium. After 24-hour incubation, the medium was replaced with
SPM in the presence or absence of 100 μg/mL MG-BSA-AGEs or non-
modiﬁed BSA and incubated for a further 72 h. Each condition was
performed in duplicate, and each experiment was repeated in-
dependently three times. Total RNA was extracted using the RNeasy
Mini Kit (Qiagen Inc., Valencia, CA, USA) to quantitatively monitor the
expression of the human MMP-9 (GenBank Accession No. NM_004994.
2), RAGE (GenBank accession No. AB036432), ER-α (GenBank No. NM_
001122740.1) and ER-β (GenBank accession No. NM_001437.2) mRNAs
relative to the internal control ‘house-keeping’ gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, GenBank accession No. DQ403057)
mRNA using real-time PCR. Complementary DNAs (cDNAs) were pro-
duced from the total RNA extracts via reverse transcription using the
Transcriptor ﬁrst-strand cDNA synthesis kit (Roche Molecular Systems,
Pleasanton, CA, USA), and the reaction was performed in a Tetrad2
Thermal Cycler (Bio-Rad). The sequences of the primer pairs
(Invitrogen Life Technologies, Paisley, UK) were as follows: 5′-
CGCTACCACCTCGAACTTTG-3′ (forward, F) and 5′-
GCCATTCACGTCGTCCTTAT-3′ (reverse, R) for human MMP-9; F: 5′-
GGC TGG TGT TCC CAA TAA GG-3′ and R: 5′-TCA CAG GTC AGG GTT
ACG GTT C-3′ for human RAGE; F: 5′-TGG AGA TCT TCG ACA TGC TG-
3′ and R: 5′-TCC AGA GAC TTC AGG GTG CT-3′ for human ER-α; F: 5′-
CTC CAG CAG CAG GTC ATA CA-3′ and R: 5′-TCA GGC ATG CGA GTA
ACA AG-3′ for human ER-β; and F: 5′-TGT CAT CAT ATT TGG CAG
GTT-3′ and R: 5′-TTG GTA TCG TGG AAG GAC TCA-3′ for human
GAPDH. The primers were designed using primer3 software (http://
simgene.com/Primer3). The qRT-PCR was performed using a
QuantiTect Reverse Transcription kit containing PCR SYBRGreen
Master Mix (Applied Biosystems, Grand Island, NY, USA) and per-
formed on a 7500 real-time PCR system (Applied Biosystems). For each
analysis, a negative control was prepared using all reagents except the
cDNA template. All reactions were performed in triplicate.
2.11. Confocal laser scanning microscopy
Cells (1 × 103) were grown in an 8-well μ-Slide (Ibidi, Planegg-
Martinsried, Germany) in complete medium. After 24-hour incubation,
the medium was replaced with SPM in the presence or absence of
100 μg/mL MG-BSA-AGEs or non-modiﬁed BSA and incubated for 6,
24, 48, and 72 h. Each condition was performed in triplicate. Cells were
ﬁxed with 3.7% formalin for 10 min at room temperature then washed
twice with PBS and permeabilized with 0.1% Triton X-100 in PBS for
15 min after which cells were again washed twice with PBS. For ER-α
detection, the cells were incubated overnight with rabbit anti-ERα
polyclonal antibody. After washing with PBS, an additional mixture of
cells and Alexa Fluor®-488-conjugated goat-anti-rabbit antibody
(Thermo Fisher Scientiﬁc, USA) was produced to visualize ER-α. Nuclei
were stained with 0.5 μg/mL Hoechst 33342 dye. ER-α expression and
location was examined by confocal scanning microscopy using a Zeiss
LSM 780 system (Carl Zeiss, Jena, Germany) equipped with 40× oil-
immersion objective.
2.12. ER-α transcription factor activation assay
MCF-7 cells (6 × 105/2 mL) were seeded in 6-well plates in com-
plete medium. After a 24-hour incubation, the medium was replaced
with SPM in the presence or absence of 100 μg/mL MG-BSA-AGEs or
non-modiﬁed BSA and further incubated for 48 h. Each condition was
performed in duplicate, and each experiment was repeated in-
dependently three times. Nuclear proteins were extracted using nuclear
protein extraction kit according to the manufacturer's instructions
(#ab113474, Abcam). Nuclear proteins containing ER-α were assessed
for ER-α transcription factor activation assay according to the manu-
facturer's instructions (#ab207203, Abcam) based on ER-α bound to a
speciﬁc double stranded DNA sequence containing the ER consensus
binding site (5′-GGTCACAGTGACC-3′).
2.13. RAGE neutralization
Cells were treated with an anti-RAGE antibody to neutralize the
RAGE receptors according to the experimental conditions previously
described in [17]. Brieﬂy, MCF-7 cells were seeded in 6-well plates in
complete medium (as described above for the Western blots). The
medium was replaced with SPM, and then 20 μg/mL mouse monoclonal
anti-RAGE [E-1] antibody or 20 μg/mL of IgG1, which was used as an
isotype control, were added. After 2-h incubation, the cells were treated
with 100 μg/mL MG-BSA-AGEs for 10 min or 72 h at 37 °C, and then
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the proteins were extracted for Western blotting. Each condition was
performed in triplicate, and each experiment was repeated in-
dependently three times.
2.14. Statistical analysis
The results are expressed as the mean ± standard deviation (SD).
Data points were collected for a minimum of three independent ex-
periments. An unpaired Student's t-test was used to compare two groups
and a value of p < 0.05 considered signiﬁcant.
3. Results
3.1. MG-BSA-AGEs modulate MCF-7 cell proliferation
We ﬁrst evaluated the biological impact of increasing concentra-
tions (25–200 μg/mL) of either non-modiﬁed bovine serum albumin
(BSA) or MG-BSA-AGEs on ER-positive breast cancer cell line MCF-7
proliferation, key cellular event involved in breast cancer development
(Fig. 1). Compared to the untreated control cells, MG-BSA-AGEs in-
creased then decreased MCF-7 cell proliferation (producing a bell-
shaped curve) with peak stimulation in the presence of 50 and 100 μg/
mL MG-BSA-AGEs (35% increase, p < 0.01) (Fig. 1A). At the lowest
concentration (25 μg/mL), MG-BSA-AGEs had no eﬀect on cell pro-
liferation, whereas a marked inhibition of cell growth (17.0% decrease,
p < 0.05) was observed at the highest concentration (i.e. 200 μg/mL)
of MG-BSA-AGEs compared to the untreated control cells (Fig. 1A).
Furthermore, the percentage of cell viability was determined by the
trypan blue exclusion method (Fig. 1B). Under all conditions tested, a
high percentage of cell viability was observed, and neither MG-BSA-
AGEs nor non-modiﬁed BSA exerted cytotoxic eﬀects (Fig. 1B).
We sought to determine the molecular mechanism underlying the
inhibitory eﬀects mediated by 200 μg/mL MG-BSA-AGEs on cell pro-
liferation. After 72 h of incubation, whole proteins were extracted from
untreated MCF-7 cells and cells treated with either 200 μg/mL non-
modiﬁed BSA or MG-BSA-AGEs for Western blot analysis. Targeting
pro-caspase-3 activation, responsible of the hallmarks of the pro-
grammed cell death (i.e. apoptosis), we detected cleaved caspase-3
(200 μg/mL) in MG-BSA-AGEs-treated cells while no cleaved caspase-3
was detected in untreated cells and cells treated with 200 μg/mL non-
modiﬁed BSA (Fig. 1C).
3.2. MG-BSA-AGEs increase MCF-7 cell migration without aﬀecting cell
invasion
Having established that MG-BSA-AGEs enhance MCF-7 cell pro-
liferation, their eﬀect on MCF-7 cell migration, a key cellular function
involved in cancer progression, was assessed. The Boyden chamber
assay was used to evaluate the eﬀect of the MG-BSA-AGEs on MCF-7
cell migration, based on a directional approach. MCF-7 cells were in-
cubated in the presence of non-modiﬁed BSA or MG-BSA-AGEs at in-
creasing concentrations (25–200 μg/mL) for 24 h (Fig. 2). Re-
presentative photomicrographs of the stained MCF-7 cells that migrated
through the porous membrane at the end of the 24-hour treatment
without (Fig. 2A) or with either 100 μg/mL non-modiﬁed BSA (Fig. 2B)
or 100 μg/mL MG-BSA-AGEs (Fig. 2C) are shown in Fig. 2. At all con-
centrations tested, non-modiﬁed BSA had no eﬀect on MCF-7 direc-
tional cell migration compared to the control (Fig. 2D). With an in-
creasing concentration, MG-BSA-AGEs increased then decreased
directional MCF-7 cell migration (producing a bell-shaped curve) with
peak stimulation in the presence of 100 μg/mL MG-BSA-AGEs (2.1-fold;
p < 0.001) compared to the control (Fig. 2D). At the lowest (25 μg/
mL) and the highest (200 μg/mL) concentrations, the MG-BSA-AGEs did
not signiﬁcantly change the number of migrated cells compared to
untreated control cells (Fig. 2D).
Although MCF-7 cells are known for their low invasive and meta-
static potential [33], the invasion method consisted of the Boyden
chamber assay with the porous membrane coated with growth factor-
reduced Matrigel™ was used to determine whether the addition of MG-
BSA-AGEs would stimulate cell invasiveness. After 24 h of incubation,
MCF-7 cells were not able to invade the porous membrane at all con-
centrations of MG-BSA-AGEs used (25–200 μg/mL; data not shown).
The lack of invasive potential was conﬁrmed by the absence of active
forms of matrix metalloproteinases (MMP)-9 and MMP-2, key enzymes
involved in the invasive process through degradation of extracellular
matrix proteins, revealed using gelatin-substrate zymography from
MCF-7 cell-condition medium (Fig. 2E). However, compared with the
Fig. 1. Eﬀects of MG-BSA-AGEs and non-modiﬁed BSA on (A) the proliferation and (B)
the viability of MCF-7 breast cancer cells. The cells were treated with 25–200 μg/mL MG-
BSA-AGEs or non-modiﬁed BSA for 72 h. Cell number (A) and cell viability (B) were
determined using an automated cell counter and the trypan blue exclusion method, re-
spectively. Control comprises untreated cells. The results are presented as mean ± SD
(n= 3). (*) and (**) signify a statistically signiﬁcant diﬀerence (p < 0.05 and p < 0.01
respectively) compared with the control. (C) Representative Western blot analysis
showing the cleavage of pro-caspase-3 induced by 200 μg/mL MG-BSA-AGEs while no
cleaved-caspase-3 was detected in untreated cells or cells treated with 200 μg/mL non-
modiﬁed BSA after 72-hour incubation. GAPDH was used as the loading control.
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Fig. 2. Eﬀects of MG-BSA-AGEs and non-modiﬁed BSA on the directional migration of MCF-7 breast cancer cells and on gelatinase (MMP-9/MMP-2) activity. Representative photo-
micrographs (×100 magniﬁcation) showing MCF-7 cells that migrated across a 0.1% gelatin-coated porous membrane after 24 h of incubation in the absence (A) or the presence (B) of
100 μg/mL non-modiﬁed BSA or (C) 100 μg/mL MG-BSA-AGEs. Scale bar = 100 μm. (D) Quantiﬁcation of the number of migrated untreated cells and cells treated with 25–200 μg/mL of
non-modiﬁed BSA or MG-BSA-AGEs. The results are presented as the mean ± SD (n= 4). (E) Representative gelatine zymographic analysis showing the MMP-9 and MMP-2 activities
from 25 to 200 μg/mL of MG-BSA-AGE-treated MCF-7 cell-condition media, compared with untreated cell-condition medium (control). The gels revealed gelatinolytic activities of the
inactive form of MMP-9 (pro-MMP-9) and MMP-2 (pro-MMP-2), identiﬁed by their respective recombinant human rhMMP. (F) Quantiﬁcation of relative gelatinolytic activity of pro-
MMP-9 and of pro-MMP-2 expressed as relative activity, which was calculated as a ratio of the control. The results are presented as the mean ± SD (n= 3). (G) Relative expression of
MMP-9 mRNA was determined using qRT-PCR analysis in MCF-7 cells following a 24 hour-treatment with either 100 μg/mL non-modiﬁed BSA or MG-BSA-AGEs, calculated as a ratio of
GAPDH mRNA and normalized to the control. The results are presented as the mean ± SD (n= 3). (*) and (**) signify a statistically signiﬁcant diﬀerence (p < 0.05 and p < 0.01
respectively), compared with the control.
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pro-MMP-9 activity in untreated MCF-7 cell-condition medium (con-
trol), treatment with 100 μg/mL MG-BSA-AGEs signiﬁcantly enhanced
pro-MMP-9 activity (2.26-fold, p < 0.05), which is the precursor and
inactive form of MMP-9 (Fig. 2F). This pro-MMP-9 capacity in lysing
gelatin substrate is believed to be due to the exposure of its intrinsic
activity by autocatalytic cleavage [34]. In addition, performing qRT-
PCR after 24-hour incubation, 100 μg/mL MG-BSA-AGEs signiﬁcantly
up-regulated MMP-9 mRNA (2.2-fold, p < 0.01) as compared to un-
treated control cells (Fig. 2G). No change of MMP-9 mRNA was ob-
served in non-modiﬁed BSA-treated cells (Fig. 2G).
3.3. MG-BSA-AGEs increase the phosphorylation of signaling proteins
To assess the eﬀect of either non-modiﬁed BSA or MG-BSA-AGEs
(25-200 μg/mL) on signaling pathways in cultured MCF-7 cells,
Western blotting was performed to determine the levels of ERK1/2
phosphorylation (p-ERK1/2) after a 10-minute treatment, optimal in-
cubation time deﬁned from pilot studies (data not shown). Non-mod-
iﬁed BSA had no eﬀect on the ERK1/2 phosphorylation in MCF-7 cells
at any of the concentrations used, compared to untreated control cells
(Fig. 3). In contrast, MG-BSA-AGEs modulated the level of ERK1/2
phosphorylation in a dose-dependent manner (Fig. 3A). The addition of
50 μg/mL or 100 μg/mL MG-BSA-AGEs induced maximal expression of
p-ERK1/2 (1.4-fold) compared to the control (Fig. 3B). At the highest
concentration (200 μg/mL), MG-BSA-AGEs signiﬁcantly decreased
ERK2 phosphorylation (0.75-fold, p < 0.05, Fig. 3B).
A wider investigation of the proteins phosphorylated in response to
MG-BSA-AGEs/RAGE interaction was also performed using KPSS-1.3
phospho-protein array analysis. A total of 35 phospho-proteins were
analyzed in whole cell lysates of untreated MCF-7 cells (control,
Fig. 4A) or cells treated with 100 μg/mL MG-BSA-AGEs (Fig. 4B) or
100 μg/mL non-modiﬁed BSA (Fig. 4C). Compared to Western blot
analysis, the quantitative immunoblots showed that the MG-BSA-AGEs
induced 1.17-fold and 1.3-fold increases in p-ERK1 and p-ERK2 ex-
pression, respectively, compared to untreated control cell lysates
(Fig. 4D). The MG-BSA-AGEs increased phosphorylation of mitogen-
activated protein kinase (MAPK)/ERK protein-serine kinase 1/2
(MKK1/2), an upstream kinase activator of ERK1/2, and of cAMP re-
sponse element binding protein 1 (CREB1), which were reported to be
associated with breast cancer development [27], by 2.04-fold and 1.98-
fold compared to untreated control cells, respectively (Fig. 4D).
The analysis of the KPSS-1.3 phospho-protein array also included
assessment of the phosphorylation of protein-serine kinase C (PKC)
isoforms, such as PKCα, PKCα/β2, PKCε, and PKCδ, which have been
shown to play diﬀerent roles in breast cancer progression [35]. The 10-
minute treatment with MG-BSA-AGEs induced a down-regulation of the
phosphorylation of PKCε (Fig. 4B and E), whereas non-modiﬁed BSA
up-regulated PKCε phosphorylation by 1.75-fold compared to untreated
control cells (Fig. 4B and E). Compared to the control (Fig. 4A), the cells
treated with MG-BSA-AGEs also showed a 50% decrease in the phos-
phorylation of PKCα, PKCα/β2, and PKCδ (Fig. 4B and E). The phos-
phorylation of mitogen- and stress-activated protein-serine kinase 1
(Msk1), an activated downstream kinase of ERK1/2 and p38 pathways
involved in cell survival, proliferation and diﬀerentiation, and adducin
α, a cytoskeleton protein that dissociates from F-actin and spectrin
during cell migration, was also down-regulated by 50% (Fig. 4E) in
MCF-7 cells after treatment with MG-BSA-AGEs (Fig. 4B) compared to
untreated control cells (Fig. 4A). However, the level of phosphorylation
of PKCα, PKCα/β2, PKCδ, Msk1 and adducin α detected in MG-BSA-
AGEs-treated MCF-7 cells was 20-50% lower than the levels of these
phospho-proteins detected in non-modiﬁed BSA-treated MCF-7 cells
(Fig. 4E).
3.4. MG-BSA-AGEs up-regulate RAGE and ER expression in MCF-7 cells
through RAGE
To check whether MG-BSA-AGEs (100 μg/mL) up-regulate expres-
sion of RAGE and estrogen receptors, two types of receptors described
to play major roles in breast cancer development and progression
[36–37]; Western blotting, qRT-PCR, and FACS analysis were applied.
MG-BSA-AGEs up-regulated RAGE and estrogen receptor (ER)-α/β
protein expression in a time-dependent manner (Fig. 5A). At all in-
cubation times (24, 48 and 72 h), in untreated control conditions or in
the presence of non-modiﬁed BSA (100 μg/mL), no change of RAGE
protein expression was observed as compared to RAGE basal expression
level detected in untreated control cells at 24 h. Compared to the RAGE
basal expression level, MG-BSA-AGEs up-regulated by 1.3-fold and 1.5-
fold RAGE expression at 48 and 72-hour post-treatment, respectively
(Fig. 5B). With regards to ER-α, its expression increased by 1.3-fold
with (at all incubation times) or without addition of non-modiﬁed BSA
(48–72 h of treatment), compared to basal ER-α expression level de-
tected in untreated control cells at 24 h. At all incubation times, MG-
BSA-AGEs enhanced ER-α protein expression in a time-dependent
manner (Fig. 5A). MG-BSA-AGEs increased ER-α protein expression by
1.3-, −1.5 and −1.7-fold after 24, 48 and 72 h, respectively; with a
signiﬁcant diﬀerence (p < 0.05) between 48 and 72 hour time-points,
as compared to the basal ER-α expression in untreated control cells at
24 h (Fig. 5B). With regards to ER-β, its expression increased (1.6-fold,
p < 0.01) in untreated conditions after 48 and 72 h, compared to basal
ER-β expression detected in untreated control cells after 24 h. Over the
time, the addition of non-modiﬁed BSA increased ER-β expression by
1.6-fold after 24 h then decreased progressively reaching the basal ER-β
expression after 72 h as compared to the ER-β basal expression level
detected in untreated control cells at 24 h (Fig. 5B). Conversely, a sig-
niﬁcant decrease in ER-β expression (0.75-fold and 0.87-fold) was ob-
served after cells were treated with MG-BSA-AGEs for 24 and 48 h re-
spectively. However, an increase in ER-β expression (1.26-fold) was
only observed after 72 h compared with the respective basal expression
detected in untreated control cells at 24 h (Fig. 5B). The mRNA ex-
pression of RAGE, ER-α and ER-β were monitored using qRT-PCR after
72 h of treatment. Compared with the basal level obtained in untreated
cells, no statistically signiﬁcant diﬀerences were observed in the non-
Fig. 3. Eﬀect of MG-BSA-AGEs on the phosphorylation of ERK1/2 in MCF-7 cells. (A)
Representative Western blot analysis showing the phosphorylation of ERK1/2 (p-ERK1/2)
induced by increasing concentrations (25–200 μg/mL) of either non-modiﬁed BSA or MG-
BSA-AGEs after a 10-minute incubation compared to the untreated control cells. (B) The
bar graph shows the expression of p-ERK1/2 relative to control cells given an arbitrary
value of 1.0 using total ERK1/2 (t-ERK1/2) as the loading control. The results are pre-
sented as mean ± SD (n= 3) where (*) and (**) signify a statistically signiﬁcant dif-
ference (p < 0.05 and p < 0.01 respectively), compared with the control.
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modiﬁed BSA-treated cells (Fig. 5C). However, in the MG-BSA-AGEs-
treated cells, signiﬁcant increases in the levels of RAGE (1.3-fold,
p < 0.001), ER-α (3.3-fold, p < 0.01) and ER-β (2.1-fold, p < 0.001)
transcripts were obtained (Fig. 5C), supporting the up-regulation of the
respective protein expression observed using Western blotting
(Figs. 5B).
FACS analysis was performed to detect RAGE expression on the
surface or inside (after membrane permeabilization) the MCF-7 cells
Fig. 4. Eﬀects of MG-BSA-AGEs on the phosphorylation of signaling proteins, including MAPK, CREB1 and PKC, in MCF-7 cells. Multi-immunoblotting of 35 phospho-proteins expressed
in untreated MCF-7 cells (A), cells treated with 100 μg/mL MG-BSA-AGEs (B) or cells treated with 100 μg/mL non-modiﬁed BSA (C), for 10 min. (D) The bar graph shows the relative
levels of phospho-cAMP responsive element binding protein-1 (CREB1) and phospho-MAPK expressed in counts per minutes, which was calculated as a ratio of relative signal intensity to
the levels detected in the untreated control cells. (E) The bar graph shows the relative expression of phospho-adducin α, phospho-Msk1 and phospho-PKC isoforms.
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after 72 h of incubation with 100 μg/mL MG-BSA-AGEs or non-mod-
iﬁed BSA. Compared with the isotype (negative) control, RAGE was
detected on the surface of untreated MCF-7 cells, and the addition of
MG-BSA-AGEs to MCF-7 cells decreased RAGE expression on the cell
surface (Fig. 6A). A greater amount of intracellular RAGE was observed
in untreated cells, but concomitant increase in intracellular RAGE ex-
pression occurred in the MG-BSA-AGE-treated cells (Fig. 6B).
Considered as the main ER inﬂuencing MCF-7 cell response to es-
trogens, only ER-α location was visualized using confocal ﬂuorescence
microscopy. Weak expression of ER-α was noticed in the cytoplasm and
the nucleus compared to the control untreated cells (Fig. 6C, top row).
Compared to ER-α basal expression detected in untreated cells after 6 h
of incubation, MCF-7 cells treated with 100 μg/mL non-modiﬁed BSA
led to a concomitant increase of ER-α expression in both cytoplasmic
and nuclear compartments observed after 48 h of treatment (Fig. 6C,
middle row). This supports the signiﬁcant increase in ER-α expression
noticed using Western blotting (Fig. 5B). In contrast to untreated MCF-7
cells and cells treated with non-modiﬁed BSA, 100 μg/mL MG-BSA-
AGEs enhanced ER-α expression following 6 h of treatment in both
cytoplasmic and nuclear compartments (Fig. 6C, bottom row). Cyto-
plasmic ER-α was predominantly high after 24 and 72 h of treatment
with MG-BSA-AGEs, while nuclear ER-α were mainly found seque-
strated into small nucleoli. After 48 h of treatment with MG-BSA-AGEs,
nuclear ER-α expression was predominantly high and mainly seque-
strated into one nucleolus site for most of the cells, considered as a site
of high transcriptional activity (Fig. 6C, bottom row). At similar con-
ditions (48 hour-treatment with MG-BSA-AGEs vs. non-modiﬁed BSA),
ER-α transcription factor activation based on the recognition of the
Fig. 5. Time-course of RAGE, ER-α and ER-β protein and
mRNA expression in MCF-7 breast cancer cells treated with
MG-BSA-AGEs. (A) Representative Western blot showing
the eﬀect of 100 μg/mL non-modiﬁed BSA or 100 μg/mL
MG-BSA-AGEs on RAGE, ER-α and ER-β protein expression
in MCF-7 cells after incubation for 24, 48 or 72 h compared
to the untreated control cells. (B) The bar graph shows the
relative protein expression of RAGE, ER-α and ER-β calcu-
lated as a ratio of GAPDH expression (the loading control)
and normalized to the control. (C) Relative expression of
the RAGE, ER-α and ER-β mRNAs was determined using
qRT-PCR analysis in MCF-7 cells following a 72-hour
treatment with 100 μg/mL non-modiﬁed BSA or 100 μg/mL
MG-BSA-AGEs, calculated as a ratio of GAPDH mRNA and
normalized to the control. The results are presented as the
mean ± SD (n= 3) where (*), (**) and (***) signify a
statistically signiﬁcant diﬀerence (p < 0.05, p < 0.01
and p < 0.001 respectively) compared to the control.
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Fig. 6. Eﬀect of MG-BSA-AGEs on cellular distribution of RAGE and ER-α expression in MCF-7 cells. (A) Representative FACS results showing the eﬀect of 100 μg/mL MG-BSA-AGEs on
FITC-conjugated RAGE expression on the surface of non-permeabilized MCF-7 cells or inside the permeabilized MCF-7 cells after 72 h of incubation compared to the untreated control. An
isotype control antibody FITC-conjugated IgG1 was used to establish the FACS instrument settings. (B) The bar graph shows mean ± SD of the percentage of RAGE-positive cells in MG-
BSA-AGEs-treated permeabilized and non-permeabilized MCF-7 cells, compared to untreated control cells (n= 4). (C) Representative photomicrographs showing cytoplasmic and nuclear
locations of ER-α protein expression (green ﬂuorescence) in untreated MCF-7 cells (top row), in MCF-7 cells treated with either 100 μg/mL non-modiﬁed BSA (middle row) or MG-BSA-
AGEs (bottom row) after diﬀerent incubation times (from 6 to 72 h). White arrows indicate ER-α sequestration into the nucleoli. Scale bar = 20 μm. (D) The bar graph shows mean ± SD
for the absorbance (measured at 450 nm) reading of the level of ER-α transcription factor activation in MG-BSA-AGEs-treated MCF-7 cells after 48 h of treatment, compared to non-
modiﬁed BSA-treated cells and untreated control cells (n= 3). (*) signiﬁes a statistically signiﬁcant diﬀerence (p < 0.05) compared with the control.
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antibody directed to ER-α bound to a speciﬁc double stranded DNA
sequence containing the ER consensus binding site was assessed.
Compared to ER-α, transcription factor activation seen in untreated
MCF-7 cells or cells treated with non-modiﬁed BSA, the level of ER-α
transcription factor activation increased (1.15-fold, p < 0.05) in MCF-
7 cells treated with MG-BSA-AGEs for 48 h of incubation (Fig. 6D).
To check whether MG-BSA-AGEs stimulated MCF-7 cells through
their major receptor RAGE, the cells were pre-treated with either a
neutralizing RAGE antibody to block all the RAGE molecules or with an
isotype control IgG1 used as a negative control (Fig. 7). After the
blockade of RAGE function using anti-RAGE antibody, MG-BSA-AGEs
lost its stimulatory eﬀects on ERK1/2 phosphorylation and on RAGE
and ER-α expression, whereas MG-BSA-AGEs increased ERK1/2 phos-
phorylation and up-regulated RAGE and ER-α expression in IgG1-
treated cells, demonstrating that MG-BSA-AGEs act through RAGE
(Fig. 7).
4. Discussion
Diabetes mellitus and cancer are causes for concern due to their
high incidence in Western countries and, more recently, in developing
countries. Currently, there is growing evidence of molecular links be-
tween diabetes mellitus and breast cancer [15–17]. Mainly generated
under hyperglycemic conditions and by active cancerous cells, AGEs
represent the main toxic and inﬂammatory metabolites playing a pi-
votal role in the cause-and-eﬀect between diabetes and cancer. Al-
though ER-positive breast cancer has a better prognosis, a study re-
ported a direct correlation between type 2 diabetes and ER-positive
breast cancer onset and development [32,38]. In order to improve our
understanding of the role of AGEs on ER-positive breast cancer pro-
gression, this study investigated the biological eﬀects of MG-BSA-AGEs
on ER-positive MCF-7 human breast cancer cell line. Here, we show that
50-100 μg/mL MG-BSA-AGEs slightly increase MCF-7 cell proliferation
and migration without aﬀecting cell invasion, while 200 μg/mL MG-
BSA-AGEs induced apoptosis leading to the cleavage of caspase-3.
Furthermore, the MG-BSA-AGEs increase expression of RAGE, ER-α and
ER-β, and the phosphorylation of key signaling proteins including
ERK1/2. In addition, the blockade of RAGE using a neutralizing RAGE
antibody reverses MG-BSA-AGEs-induced ERK1/2 phosphorylation and
MG-BSA-AGEs-induced RAGE and ER-α up-regulation. Altogether, this
study demonstrates that the pro-tumorigenic eﬀects of AGEs on ER-
positive breast cancer cell line MCF-7 characterized by ERK1/2 phos-
phorylation, RAGE and ER-α up-regulation are mediated through RA-
GE, which likely suggests an increase of sensitivity of ER-positive breast
cancer cells to AGEs and estrogens for breast cancer development.
In this study, MCF-7 cells were treated with various concentrations
of MG-BSA-AGEs or non-modiﬁed BSA and their eﬀects on breast cancer
cellular functions such as proliferation, migration, invasion and sig-
naling pathways were determined. At concentrations of 50 and 100 μg/
mL, the MG-BSA-AGEs signiﬁcantly increased cell growth and motility,
but had an inhibitory mitogenic eﬀect observed at 200 μg/mL. These
dose-response eﬀects showed a bell-shaped curve, suggesting that ac-
tivation of a receptor whose optimal oligomerization occurs in the
presence of 50-100 μg/mL of MG-BSA-AGEs. These ﬁndings were si-
milar to our previous study reporting the bell-shaped dose-response of
MG-BSA-AGEs on MDA-MB-231 breast cancer cells in a RAGE-depen-
dent manner [17]. However, at higher concentration of MG-BSA-AGEs
(200 μg/mL), an impediment of RAGE oligomerization may occur as
demonstrated by other studies using biophysics and biochemical tech-
nologies, which can explain the decrease of the MCF-7 cell proliferation
[39–40]. In addition, similar high concentration of AGEs (200 μg/mL)
have been demonstrated to induce apoptosis in pancreatic islet en-
dothelial cells leading to the cleavage of caspase-3 and of poly(ADP-
ribose) polymerase (PARP) proteins, both hallmarks of apoptosis [41].
Using the gelatin zymography method, the activities of the enzymes
involved in basement membrane degradation allowing the cells to in-
vade, such as the gelatinases MMP-2 and MMP-9 were assessed. Both
MMP-2 and MMP-9 activities were evaluated in the conditioned
medium from the MCF-7 cells after the invasion assay in the presence or
absence of diﬀerent concentrations of non-modiﬁed BSA or MG-BSA-
AGEs. Under all conditions tested, non-modiﬁed BSA and MG-BSA-
AGEs did not activate MMP-2 and MMP-9. However, MG-BSA-AGEs
signiﬁcantly enhanced the amount of enzymatically inactive state pro-
MMP-9 and up-regulated MMP-9 gene expression revealed using qRT-
PCR. This absence of gelatinase MMP activation reinforces the MCF-7
weak invasive capacity only, while MG-BSA-AGEs-induced cell
Fig. 7. RAGE mediates MG-BSA-AGE-induced p-ERK1/2,
RAGE and ER-α expression in MCF-7 cells. Representative
Western blot analysis showing the loss of MG-BSA-AGE-
induced phosphorylation of (A) ERK1/2 and (C) RAGE and
ER-α after the blockade of RAGE by an anti-RAGE antibody
compared to isotype control IgG1-treated cells. Bar graphs
show the relative expression of (B) ERK1/2 and (D) RAGE
and ER-α calculated as ratio to the total ERK1/2 and
GAPDH, the respective controls. The results are presented
as mean ± SD (n= 3). (*) and (**) signify a statistically
signiﬁcant diﬀerence (p < 0.05 and p < 0.01 respec-
tively) compared with the control.
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migration can occur without MMP activation as demonstrated by
Dufour et al. [42] reporting that COS cell (ﬁbroblast-like cell line)
migration was enhanced in a non-proteolytic manner by latent pro-
MMP-9.
We also showed that 100 μg/mL MG-BSA-AGEs up-regulated RAGE
expression in MCF-7 cells, particularly after 48 and 72 h of treatment. It
is noteworthy that RAGE up-regulation occurred in the intracellular
forms of the receptor while a slight decrease of RAGE expression was
observed on the cell surface. This observation underlines the inter-
nalization of RAGE over time as previously reported using Chinese
hamster ovary cells (CHO-K1) and neuro-2 cells [43]. This RAGE in-
ternalization was demonstrated to be required to mediate intracellular
response [43]. Furthermore, in this study, RAGE up-regulation induced
by MG-BSA-AGEs was conﬁrmed by the increase of mRNA RAGE
transcripts monitored after 72 h of treatment. These ﬁndings are sup-
ported by other studies [44], where overexpression of the RAGE mRNA
and protein in human vascular endothelial cells were observed fol-
lowing treatment with MG-BSA-AGEs. The same study also demon-
strated a stimulatory eﬀect on RAGE gene expression at the transcript
level by identifying an AGE-responsive element in a region upstream
from the transcription start site of the human RAGE gene [44]. Thus,
the decreased expression of RAGE on the cell surface explains the
modest biological eﬀect of AGEs on breast cancer cells.
This present investigation of eﬀects of AGEs on ER-positive breast
cancer cells led us to monitor nuclear receptor ER-α and ER-β expres-
sion, two transcription factors that mediate estrogen signaling, in MG-
BSA-AGEs-treated MCF-7 cells at diﬀerent time-points. MG-BSA-AGEs
increased ER-α expression in MCF-7 cells with the incubation time,
while MG-BSA-AGEs down-regulated ER-β expression at 24–48 h after
treatment followed by up-regulation of ER-β expression at 72-hour
post-treatment. This up-regulation of RAGE, ER-α and ER-β induced by
MG-BSA-AGEs detected at 72-hour post-treatment was conﬁrmed by
the up-regulation of their respective transcripts mRNA. In response to
estrogen, activation of ER-α signaling results in stimulation of breast
cancer cell growth, diﬀerentiation and breast cancer progression, while
ER-β has been reported to exert a negative regulatory role for ER-α and
an anti-proliferative role in breast cancer [45–46]. These diﬀerential
eﬀects of AGEs on ER-α and ER-β expression, encoded by independent
genes, suggest that activation of diﬀerent regulatory mechanisms in-
cluding epigenetic changes are inﬂuenced under transient high glucose
or through hypermethylation of the ESR2 promoter associated with a
marked decrease of ER-β [47–48]. Τhis might explain the altered gene
expression of ER mediated by AGEs. In addition, the diﬀerent level of
ER-β expression between the protein and transcript detected in un-
treated cells can be explained by a transcriptional regulation between
ER-β mRNA transcript and the protein expressed. A study reported that
ER-β expression is often down-regulated in cancer compared to normal
cells and is negatively regulated by the microRNA miR-92 in MCF-7
cells [49]. To understand better this transcriptional regulation, a study
on miR-92 might help clarify this negative regulation on ER-β protein
expression observed in certain experimental conditions. Furthermore,
using human microvascular endothelial cells, a previous study showed
that ER-α activation triggered the activation of the SP1 transcription
factor, known to regulate the expression of pro-oxidative and pro-in-
ﬂammatory genes including the stimulation of RAGE gene expression
[50]. This latter study also demonstrated a diﬀerential eﬀect of ER-α
and ER-β agonists on RAGE expression [50]. In addition, Lata and
Mukherjee [51] identiﬁed a key role for RAGE in stimulating the pro-
liferation and survival of MCF-7 cells induced by 17α-ethinyl-estradiol,
an ER-α agonist. Moreover, in this present study, the location of ER-α
(major ER involved in breast cancer development) visualized using
confocal ﬂuorescence microscopy showed a massive translocation of
ER-α from the cytoplasm to the nucleus after 48 h of treatment with
AGEs, with a predominant sequestration into a large nucleolus, site of
high transcriptional activity [52]. In addition, in this study, a slight
increase of ER-α transcription factor activation in MCF-7 was also
observed after 48 h of treatment with AGEs. ER-α was found seque-
strated in multiple small nucleoli at 24- and 72-hour post-treatment
with AGEs. Collectively, these results suggest that the MG-BSA-AGEs
might contribute to the growth of breast cancer by synergizing with ER-
α activation.
With regards to the signaling pathways activated through AGEs/
RAGE axis, the phospho-proteome proﬁle of MG-BSA-AGEs-treated
MCF-7 cells, luminal breast cancer cell line expressing ER, was far less
detectable in contrast to MG-BSA-AGEs-treated MDA-MB-231 cells,
basal subtype lacking ER expression, in which increased phosphoryla-
tion of p70S6K1, STAT3, p38 MAPK, GSK3 and MKK1/2 were mainly
detected, as compared to untreated MDA-MB-231 cells [17]. This dif-
ference signaling activation between MCF-7 and MDA-MB-231 cells
align with the reported fact that the most aggressive and highly pro-
liferated basal ER-negative sub-type MDA-MB-231 expresses the highest
level of RAGE in contrast to the less aggressive luminal ER-positive sub-
type MCF-7, which showed the lowest level of RAGE expression [53]. In
this study using MCF-7 cells, we showed that the MG-BSA-AGEs mainly
enhanced the phosphorylation of ERK1/2, MAPK kinase 1/2 (MKK1/2,
an activator of phospho-ERK1/2), while MG-BSA-AGEs decreased the
phosphorylation of mitogen and stress-activated protein-serine kinase 1
(Msk1, a CREB1 substrate), of diﬀerent phospho-PKC isoforms (i.e.
PKCα, PKCδ and PKCε), and of adducin α (a PKCδ substrate), respec-
tively reported to play a central role in transcription/translation/in-
ﬂammatory responses/neuronal processes [54], in cell cycle progres-
sion/tumorigenesis/metastatic dissemination [55], and in breast cancer
progression [56]. Unlike the important kinases implicated in cancer
development and progression such as ERK1/2, the phosphorylation of
Msk1, which plays a versatile role in transcriptional regulation, and
phosphorylation of PKCs have been reported to not necessarily corre-
late with activation status [51–52]. However, both ERK1/2 and CREB1
are considered as key regulatory proteins in AGEs-promoting cancer
including melanogenesis [27]. Furthermore, MG-BSA-AGEs enhance
the phosphorylation of ERK1/2 and its upstream activator MKK1/2 in
MCF-7 cells at lower levels than those previously detected in MDA-MB-
231 cells [17]. The diﬀerence in the signaling intensity between the
MCF-7 and MDA-MB-231 cells, based on phospho-ERK1/2 over-
expression induced by BSA-AGEs, was also seen after chemotherapy
with doxorubicin or docetaxel [57]. In addition, MG-BSA-AGEs up-
regulated the expression of phospho-CREB1, a transcription factor in-
volved in cell stress responses, cell survival and proliferation. Recently,
CREB1, a known ERK2 substrate, has been shown to contribute to
breast malignancy by inducing transcription of the aromatase enzyme
in breast adipose mesenchymal cells, which leads to increased estrogen
levels and, subsequently to cancer development [58–59]. It would
therefore be of interest to investigate the impact of MG-BSA-AGEs on
the convergence and functional collaboration of ER-α and ERK2 at the
genome level that were previously described in MCF-7 cells [60].
In conclusion, we described the stimulatory eﬀects of MG-BSA-AGEs
on the proliferation and migration of the hormone-dependent ER-po-
sitive breast cancer cell line MCF-7. The investigation of the signaling
pathways indicates that MG-BSA-AGEs mainly activate the MAPK
pathway and induces the phosphorylation of CREB1 transcription factor
in MCF-7 cells; ERK1/2 and CREB1 being widely reported as the main
signaling molecules involved in breast cancer development and pro-
gression. In addition, MG-BSA-AGEs up-regulate RAGE and ER-α ex-
pression through RAGE, suggesting a hypersensitivity of MCF-7 cells to
estrogen following to AGEs exposure. Altogether, these ﬁndings suggest
the need for further studies investigating whether the exposure of AGEs-
treated ER-positive breast cancer cells to estrogen could lead to an
enhancement of breast cancer development and progression in diabetic
patients.
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